N,N,N-三丁基-1-丁烷铵2-氨基-6-碘嘌呤-9-I去 | 156126-48-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: N,N,N-三丁基-1-丁烷铵2-氨基-6-碘嘌呤-9-I去
• 英文名称: 2-amino-6-iodopurine tetra-n-butylammonium salt
• 英文别名: 2-amino-6-iodopurine tetrabutylammonium salt；tetra (n-butyl) ammonium salt of 6-iodo-2-aminopurine；tetra(n-butyl)ammonium salt of 6-iodo-2-aminopurine；tetrabutylammonium salt of 2-amino-6-iodopurine；6-iodo-2-aminopurine tetrabutylammonium salt；6-Iodo-9H-purin-2-amine ion(1-) tetrabutylammonium salt；Tetrabutylammonium 2-amino-6-iodopurinate；6-iodopurin-9-id-2-amine;tetrabutylazanium
• CAS: 156126-48-6
• 化学式: C₅H₃IN₅*C₁₆H₃₆N
• 分子量: 502.485
• InChiKey: ULQTXQCQROFQIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.17
• 重原子数：
  28
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  65.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2R,4aR,7S,8R,8aR)-8-fluoro-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-yl trifluoromethanesulfonate 、 N,N,N-三丁基-1-丁烷铵2-氨基-6-碘嘌呤-9-I去 以 六甲基磷酰三胺 为溶剂， 反应 18.0h， 以75%的产率得到
  参考文献：
  名称：

  TETRAHYDROPYRAN NUCLEIC ACID ANALOGS

  摘要：

  本公开描述了四氢吡喃核苷类似物，以及由此制备的寡聚合物化合物和使用这些寡聚合物化合物的方法。更具体地说，提供了具有一个或多个手性取代基的四氢吡喃核苷类似物，这些类似物可用于增强包括核酸酶抗性和结合亲和性在内的寡聚合物化合物的性质。在某些实施例中，本文提供的寡聚合物可以与目标RNA的部分杂交，导致目标RNA失去正常功能。

  公开号：

  US20090092981A1
• 作为产物：
  描述：

  四丁基氢氧化铵 、 2-氨基-6-碘嘌呤 以 二氯甲烷 为溶剂， 生成 N,N,N-三丁基-1-丁烷铵2-氨基-6-碘嘌呤-9-I去
  参考文献：
  名称：

  Purinyl salts useful for preparing guanine containing antiviral agents

  摘要：

  一种嘌呤盐的化学式为##STR1##，其中Y.sub.1是氯、溴或碘，而R.sub.1、R.sub.2、R.sub.3和R.sub.4是独立选择的烷基和取代烷基。

  公开号：

  US05608064A1

文献信息

• Process for preparing guanine-containing antiviral agents and purinyl
  申请人：Bristol-Myers Squibb

  公开号：US05874578A1

  公开（公告）日：1999-02-23

  A purine salt of the formula ##STR1## wherein Y.sub.1 is chloro, bromo, or iodo, and R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are independently selected from alkyl and substituted alkyl is reacted with the compound of the formula Z.sub.1 --X to yield the purine of the formula ##STR2## wherein x is a leaving group, and Z.sub.1 is a protected form of the carbohydrate surrogate Z. Several routes are disclosed for converting this intermediate to the antiviral agent ##STR3##

  一种配方为##STR1##的嘌呤盐，其中Y.sub.1为氯、溴或碘，而R.sub.1、R.sub.2、R.sub.3和R.sub.4分别选自烷基和取代烷基，与配方为Z.sub.1--X的化合物反应，生成配方为##STR2##的嘌呤，其中x为脱离基团，Z.sub.1是碳水化合物替代物Z的保护形式。揭示了将这种中间体转化为抗病毒剂##STR3##的几种途径。
• Asymmetric Synthesis of Cyclobutanones: Synthesis of Cyclobut-G
  作者：Benjamin Darses、Andrew E. Greene、Jean-François Poisson

  DOI：10.1021/jo202261z

  日期：2012.2.17

  efficient, and stereoselective approach has been developed for obtaining chiral cis- and trans-disubstituted cyclobutanones from readily available alkyl- and functionalized alkyl-substituted enol ethers. The usefulness of these cyclobutanones is illustrated by an enantioselective synthesis of cyclobut-G (Lobucavir).

  已经开发了一种简单，有效和立体选择性的方法，用于从容易获得的烷基和官能化的烷基取代的烯醇醚中获得手性的顺式和反式二取代的环丁酮。这些环丁酮的有用性通过环丁-G（洛布卡韦）的对映选择性合成来说明。
• Antiviral tetrahydropyrans
  申请人：Bristol-Myers Squibb Co.

  公开号：US05314893A1

  公开（公告）日：1994-05-24

  Compounds of the formula ##STR1## wherein R.sub.1 is an amino substituted pyrimidinone or a pyrimidinedione including pharmaceutically acceptable salts are useful as antiviral agents.

  公式为##STR1##的化合物，其中R.sub.1是氨基取代的嘧啶酮或嘧啶二酮，包括药用可接受的盐，可用作抗病毒剂。
• Hexitol Nucleic Acids (HNA): Synthesis and Properties
  作者：B. De Bouvere、L. Kerreinans、C. Hendrix、H. De Winter、G. Schepers、A. Van Aerschot、P. Herdewijn

  DOI：10.1080/07328319708006119

  日期：1997.7

  While improved alkylation procedures have been worked out for the coupling of purine bases to the anhydrohexitol ring using sulphonate activating groups on the anhydrohexitol ring, the Mitsunobu reaction seems to be the method of choice for synthesis of the pyrimidine analogues. In a mixed sequence context, the anhydrohexitol oligonucleotides still display strong and very selective basepairing properties, with a strong preference for RNA as the complement.
• A Practical Asymmetric Synthesis of the Antiviral Agent Lobucavir, BMS-180194
  作者：Janak Singh、Gregory S. Bisacchi、Saleem Ahmad、Jollie D. Godfrey,、Thomas P. Kissick、Toomas Mitt、Octavian Kocy、Truc Vu、Chris G. Papaioannou、Michael K. Wong、James E. Heikes、Robert Zahler、Richard H. Mueller

  DOI：10.1021/op970214+

  日期：1998.11.1

  A practical synthesis of the antiviral agent lobucavir, [1R(1 alpha,2 beta,3 alpha)] -2-amino-9-[2,3-bis(hydroxymethyl)cyclobutyl]-6H-purin-6-one (BMS-180194), is described. The key chiral intermediate, [1S-(1 alpha,2 beta,3 alpha)]-3-hydroxy-1,2-cyclobutanedimethanol, dihenzoate ester, was made by an asymmetric [2 + 2] cycloaddition of dimenthyl fumarate with ketene dimethyl acetal followed by sequential diester reduction, benzoylation, deketalization, and stereoselective ketone reduction. Regioselective N9-alkylation of the tetra-n-butylammonium salt of 2-amino-6-iodopurine with the derived cyclobutyltriflate furnished the purinecyclobutyl dibenzoate. Methanolysis followed by acid hydrolysis produced lobucavir in a 35% overall yield with an ee, 99%.